IGC Pharma在其第二阶段试验中增加了一个新站点,测试一种大麻素药物以引起阿尔茨海默氏病的激动。 IGC Pharma adds a new site to its Phase 2 trial testing a cannabinoid drug for Alzheimer’s agitation.

IGC Pharma扩大了IGC-AD1的CALMA试验第二阶段,该试验是以大麻素为基础的治疗,治疗阿尔茨海默氏病引起的扰动,将纽约锡拉丘兹的Ichor Research作为新的研究场地。 IGC Pharma has expanded its Phase 2 CALMA trial for IGC-AD1, a cannabinoid-based therapy for Alzheimer’s-related agitation, by adding Ichor Research in Syracuse, New York, as a new study site. 该试验是随机、双盲和安慰剂控制的,目的是评估该药物在减少阿兹海默氏病患者中常见和衰弱症状的激动性方面的安全性和有效性。 The trial, which is randomized, double-blind, and placebo-controlled, aims to evaluate the drug’s safety and effectiveness in reducing agitation, a common and debilitating symptom in Alzheimer’s patients. Karl F. Hafner博士正在领导锡拉丘兹站点,该站点立即开始登记参加者。 Dr. Karl F. Hafner is leading the Syracuse site, which began enrolling participants immediately. 增加的内容强调了IGC Pharma与有经验的研究组织合作的战略,以扩大接触和推进AI驱动的输油管道,针对老年痴呆症和代谢紊乱症。 The addition underscores IGC Pharma’s strategy of partnering with experienced research organizations to broaden access and advance its AI-driven pipeline targeting Alzheimer’s and metabolic disorders.